Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Henkle

Pain Medicine Lowell, MA Medical Doctor

NPI 1669630083 CMS profile 211034

2 Hospital Dr, 2Nd Floor, Lowell, MA 01852

Open in the dashboard

General payments

$16,579

322 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Henkle of Lowell, MA is reported in the CMS Open Payments database as having received $16,579 across 322 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $756 20
2024 General $1,039 33
2023 General $6,096 81
2022 General $4,995 71
2021 General $1,492 49
2020 General $1,043 35
2019 General $1,158 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Henkle
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Benjamin Henkle were reported at $756. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Benjamin Henkle Pain Medicine median Middle half National median
2019 $1,158 $409 $115–$1,311 $163
2020 $1,043 $214 $66–$666 $114
2021 $1,492 $299 $84–$899 $132
2022 $4,995 $335 $103–$1,149 $149
2023 $6,096 $376 $114–$1,228 $160
2024 $1,039 $387 $115–$1,173 $164
2025 $756 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $10,697 123 payments
  2. Abbott Laboratories $2,121 61 payments
  3. AbbVie, Inc. $1,349 49 payments
  4. Allergan Inc. $791 37 payments
  5. Medtronic USA, Inc. $605 17 payments
  6. Ipsen Biopharmaceuticals, Inc $201 8 payments
  7. Stimwave Technologies Incorporated $180 1 payment
  8. Boston Scientific Corporation $170 7 payments
  9. TerSera Therapeutics LLC $100 4 payments
  10. Collegium Pharmaceutical, Inc. $97 5 payments
  11. Other $268 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,159 289 payments
  2. Travel and Lodging $4,210 31 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,145 1 payment
  4. Education $65 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $5,632 56 payments
  2. SYNCHROMEDII $2,457 34 payments
  3. VANTA ADAPTIVESTIM $1,601 10 payments
  4. BOTOX Botox Therapeutic $903 35 payments
  5. BOTOX Hyperhydrosis $786 37 payments
  6. INTELLIS Spinal Cord Neurostimulation $483 10 payments
  7. BOTOX Neuroscience $450 14 payments
  8. Proclaim Family of SCS IPGs $366 12 payments
  9. INTELLIS Spinal Cord Neurostimulation $339 6 payments
  10. Ascenda $242 4 payments
  11. Other $3,113 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

318

Median for Pain Management: 951

Drug cost

$4,403

Median for Pain Management: $26,034

Branded share of claims

10.7%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 114 $1,350
Pregabalin Generic 53 $953
Celecoxib Generic 13 $744
Duloxetine Hcl Generic 24 $369
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 23 $275
Amitriptyline Hcl Generic 37 $241
Clonazepam Generic 12 $210
Oxycodone Hcl Generic 11 $95
Tramadol Hcl Generic 20 $84
Acetaminophen-Codeine Acetaminophen With Codeine Brand 11 $83

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$166,137

Medicare's payments for the services billed

Medicare patients

411

Average age 69

Services billed

2,609

271 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Depression 40%
Ischemic heart disease 33%
Diabetes 30%
Chronic kidney disease 30%
COPD 25%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $378
$378 — —
Qutenza
  • Averitas Pharma Inc. $85
$85 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

322 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record